iCardio.ai announced a collaboration with Abbott (NYSE: ABT) + to develop AI applications for the medtech giant’s imaging technologies.

The collaboration aims to accelerate the integration of AI into the company’s electrophysiology imaging product line. These products help to treat patients with cardiac arrhythmias like AFib.

Los Angeles-based iCardio.ai develops machine learning and deep learning algorithms for the analysis of ultrasound applications. Its offerings have a specific focus on transthoracic echo, utilizing a database of more than 200 million images to bring AI to echocardiography.

The company expects to support Abbott’s goals of automating model creation on its EnSite X cardiac mapping system. Its algorithms can help achieve this through 2D intracardiac echo (ICE) images captured by Abbott’s ICE catheters.

Ensite X helps physicians visualize and position tools like the Abbott Volt pulsed field ablation (PFA) catheter in the heart. Abbott said the design can lead to more accurate ablation procedures with physicians given a clearer indication to make improved contact with targeted heart tissue.

“The collaboration will take advantage of iCardio.ai’s internal capabilities and in-house talents,” iCardio.ai CEO Joseph Sokol said. “This work with Abbott is aligned with our mission of bringing artificial intelligence to ultrasound. This new focus reflects the continued progress of our organization.”